As per the recently published report description published by Markntel Advisors, a leading consulting, data analytics, and market research firm, the rising prevalence of chronic diseases is expected to drive the demand for radiopharmaceuticals. This is because the changing lifestyle, obesity, and aging population boost the adoption of radiopharmaceuticals to perform diagnosis and risk assessment. Also, it facilitates monitoring the influence of therapies on heart conditions, which further propels the industry expansion. Moreover, the prevalence of cancer is increasing across the globe and this is expected to augment the demand for radiopharmaceuticals.
The further report comprises “Global Radiopharmaceuticals Market Research Report: Forecast (2024-2030)”, According to the report, the Global Radiopharmaceuticals Market is estimated to grow at a CAGR of around 10.02% during the forecast period, i.e., 2024-30. The market growth is driven by the increasing burden of the geriatric population, the incidence of multiple diseases, including cancer, cardiovascular diseases (CVDs), etc. Moreover, the adoption of radiopharmaceuticals for the diagnosis as well as the treatment of cancer, CVDs, and other diseases would increase, propelling the overall Radiopharmaceuticals Market.
Leading Segmentation Analysis Based On Radioisotope, Indication and Geography
The Radiopharmaceuticals market is segmented into four segments based on radioisotope, indication, type, and region.
- Based on Indication, the market is segmented into Oncology, Cardiology, Gastroenterology, Nephrology, and Others in upcoming years, the Oncology segment is expected to dominate the Radiopharmaceuticals Market
- Based on End-User, the market is segmented into Hospitals and Medical Imaging Centers in upcoming years, The Hospitals segment is expected to dominate the Radiopharmaceuticals Market
- Based on Geography, the market is segmented into North America, South America, Europe, Asia-Pacific, and the Middle East & Africa, in upcoming years, North America is expected to dominate the Radiopharmaceuticals Market
Growing adoption of Artificial Intelligence, Offers Futuristic Opportunities
The integration of advanced technology in radiopharmaceuticals facilitates enhancing the efficiency and proficiency of overworked radiologists, further augmenting the radiopharmaceuticals market. As with the growth economy, the shortage of radiologists, and those who are there are dealing with overwhelming workloads, often leading to burnout and compromising patient care. Additionally, AI facilitates personalized treatment planning by leveraging vast amounts of patient data, thereby enhancing the treatment outcome, and increasing patient satisfaction. This further resulted in exponential growth of the global Radiopharmaceuticals market.
Frequently Asked Questions (FAQs)-
- What is the expected CAGR value of the Radiopharmaceuticals Market during the forecast period?
- What are the trends influencing the current scenario of the Radiopharmaceuticals market?
- What key factors would propel and impede the Radiopharmaceuticals industry across the Globe?
- How has the industry been evolving in terms of geography & radiopharmaceutical adoption?
- Which region will dominate the global Radiopharmaceuticals in upcoming years?
- Who are the key competitors, and what strategic partnerships or ventures are they coming up with to stay afloat during the projected time frame?
- Which is the Leading Indication segment in the Radiopharmaceuticals market?
Have an Any Query,
Call Us – US Office: +1 628 895 8081
Email – sales@marknteladvisors.com
Address Sales Office: 564 Prospect St, B9, New Haven, Connecticut, USA-06511
Address Corporate Office: Office No.109, H-159, Sector 63, Noida, Uttar Pradesh-201301, India
Ecla Clinic